dexcom inc (DXCM) Key Developments
DexCom, Inc. - Special Call
Aug 11 15
To discuss that the company entered into an agreement with the life sciences team at Google to jointly develop a series of next-generation CGM products
DexCom, Inc. Enters Agreement with Google to Jointly Develop Series of Next-Generation CGM Products
Aug 11 15
DexCom, Inc. announced that it has entered into an agreement with the life sciences team at Google to jointly develop a series of next-generation CGM products that are designed to be smaller and less expensive than existing technologies. These new products will incorporate Google’s miniaturized electronics platform with DexCom’s best-in-class sensor technology. This collaboration also provides an opportunity to better utilize the data generated by these CGM products to significantly improve the outcomes and reduce the costs associated with diabetes care. Initial products to be developed under the agreement will focus on minimizing both the cost and size of CGM body worn components. The products will be designed to be disposable, and will be intended for use across all diabetes markets. The goal is to empower more people to control their diabetes with real-time and actionable information by developing a low-cost, small, bandage-sized sensor that is connected to the cloud.
DexCom, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015
Aug 5 15
DexCom, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenue of $93.2 million compared to $58.8 million a year ago. Operating loss was $3.6 million compared to $5.8 million a year ago. Net loss was $3.7 million or $0.05 per basic and diluted share compared to $6.0 million or $0.09 per basic and diluted share a year ago.
For the six months, the company reported total revenue of $166.0 million compared to $105.9 million a year ago. Operating loss was $16.3 million compared to $18.1 million a year ago. Net loss was $16.6 million or $0.21 per basic and diluted share compared to $18.5 million or $0.25 per basic and diluted share a year ago.
Tandem Diabetes Care Announces Development Agreement with Dexcom, Inc. for Integration of Future Generation Continuous Glucose Monitoring Systems
Jul 30 15
Tandem Diabetes Care, Inc. announced that it has entered into non-exclusive Development Agreements with Dexcom, Inc. to allow the integration of future generation Tandem insulin pumps with the Dexcom G5 and G6 continuous glucose monitoring (CGM) systems.
DexCom, Inc. to Report Q2, 2015 Results on Aug 05, 2015
Jul 16 15
DexCom, Inc. announced that they will report Q2, 2015 results at 4:30 PM, US Eastern Standard Time on Aug 05, 2015